Ilmarinen Mutual Pension Insurance Co cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 10.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 315,800 shares of the biopharmaceutical company’s stock after selling 36,700 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Bristol Myers Squibb were worth $17,034,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in BMY. waypoint wealth counsel acquired a new position in Bristol Myers Squibb in the 4th quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $34,406,000. Axxcess Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Bristol Myers Squibb by 4.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock worth $99,754,000 after purchasing an additional 93,528 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of Bristol Myers Squibb by 6.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock worth $23,972,000 after purchasing an additional 32,005 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Bristol Myers Squibb
In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by insiders.
Bristol Myers Squibb Trading Down 1.0%
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.
Analyst Ratings Changes
Several equities research analysts have issued reports on BMY shares. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Finally, Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $61.31.
Get Our Latest Analysis on BMY
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
- Five stocks we like better than Bristol Myers Squibb
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
